Anticipating breast cancer for every woman worldwide
Breast cancer, the world's #1 cancer
among women
2.3 million
670,000
Our goal:
reduce mortality by 20% **
MammoRisk® Innovation
Currently, women at risk are not identified. Moreover, 70 to 80% of breast cancers occur in women without a family history1.
MammoRisk® is a Class I medical device that assesses the risk of invasive breast cancer based on 5 main risk factors: age, family history, biopsy history, polygenic score2, and breast density.
The MammoRisk® test generates a clear and precise report estimating absolute breast cancer risk over 5 years. Based on this "risk score," physicians will collaboratively determine a personalized monitoring program with their patient (frequency and type of screening exams, hormone replacement therapies, …).
- Start of mammography: at 40 or 50 years old
- Mammography frequency: once a year, every 2 years, or none before age 50
- Annual MRI above 20% lifetime risk in the United States, i.e., about 10% of eligible women3
- See its implementation in a major hospital: video.
How does it work?
MammoRisk®, the 1st breast cancer risk prediction test, is based on 3 pillars and a patented AI method4.
Genetic test with saliva sample
By medical prescription
Medical Imaging
Patient's clinical data
Nearest neighbors method4
Artificial Intelligence
MammoRisk® a high-performance and interpretable model
Our model is based on an algorithm that identifies, for each patient, “digital twins”: age, personal and family history, breast density, in order to calculate an ultra-personalized risk of disease occurrence.
See press release on the patent
2 By medical prescription
3 https://www.cancer.org/cancer/types/breast-cancer/risk-and-prevention.html
4 Patented method that can be adapted to any database by integrating clinical, imaging, or genetic parameters.
MammoRisk®, international recognition
MammoRisk® selected by the European Union 
Our test was exclusively selected as part of the world’s only randomized clinical trial on breast cancer screening for all women over 40: the MyPeBS* study (My Personal Breast Screening).
This study aims to assess whether personalized screening based on breast cancer risk level could be a better screening option for women aged 40 to 70, with the long-term goal of transforming screening for over 100 million European women.
Learn more about the MyPeBS study
A strong barrier to entry: access to databases of over 2 million individuals
An initial breast cancer prediction model was developed using data from 100,000 French women, based on a simple and visual* method — now patented — that involves observing the outcomes of a woman’s “behavioral neighbors.”
This model, named MammoRisk®, with early AI features, was then expanded in 2013 to a database of 1,000,000 American women, allowing us to validate its effectiveness on a broader scale.
This Franco-American model was later successfully tested on 300,000 French women brought together through an initiative by the Gustave Roussy Institute, confirming its potential for application worldwide.
The Market
MammoRisk®, a blockbuster in the making
Breast cancer risk prediction targets all women over 40, in France and worldwide. Unlike treatments, prevention addresses a much broader population, encompassing all healthy women. This predictive test therefore has the potential to generate a market of considerable scale, given its reach and its positive impact on public health.
200 millionwomen may be impacted
MammoRisk®, a blockbuster in the making
Breast cancer risk prediction targets all women over 40, in France and worldwide. Unlike treatments, prevention addresses a much broader population, encompassing all healthy women. This predictive test therefore has the potential to generate a market of considerable scale, given its reach and its positive impact on public health.
200 millionwomen may be impacted
Who are we?
« When I was teaching applied mathematics in medicine and working at the Gustave Roussy cancer center, I would see patients in the hall and wonder whether we could have anticipated those illnesses. That’s when the idea was born: predicting risks to better prevent them. »
Stéphane Ragusa
Chairman and CEO
Graduate of École Polytechnique
MammoRisk is the result of 20 years of R&D. MammoRisk is owned by the Predilife group, founded in 2004, and a pioneer of predictive medicine in France. The company designs and markets predictive tests that allow each person to define their individual risk profile for the onset of serious diseases. It combines proven medical techniques with Artificial Intelligence and Big Data.
Predictive medicine aims to anticipate an individual’s future health in order to act in time through personalized prevention — either by reducing risks or by detecting disease earlier. Serious illnesses, especially cancers and heart attacks, can now be better prevented.
Scientific Board
Pr. Mahasti Saghatchian
Associate Professor at Paris Descartes University. Head of the AHP Oncology Division
Pr. Bruno Boyer
Professor of Radiology
Dr M-C Boutron-Ruault
Research Director, French medical research institute
Dr. Stella Carpentier
Gynecologist, specialization in oncogenetics
Executive Team
Stéphane RAGUSA
Founder & CEO
Marion RENELIER
Chief Financial & Legal Officer
Anne KERZAN
Chief Marketing Officer
Émilien GAUTHIER
Chief Technical Officer
Our Partners
Our Accreditations and Certifications
Our medical device is registered with the ANSM.
Our medical device complies with the essential requirements set by European regulations (CE marking).
What women think
- "I really appreciated this assessment, and the medical support was of high quality. I felt supported, and it helped me take steps I wouldn’t have dared take on my own."
- "Smooth, clear, and efficient process. Reassuring assessment that brought me peace of mind."
- "Simple, fast, and incredibly useful."